ストックスクリーナーアプリを入手
0.6665
2.70%
0.0175
アフターアワーズ：
.67
0.0035
+0.53%
Outlook Therapeutics Inc (OTLK) 最新ニュース
AMZN: Amazon.com Inc Latest Stock Price, Analysis, News and Trading Ideas - stocktwits.com
These 3 Stocks Led Wall Street’s Biggest Gains On Tuesday – Here’s Why - stocktwits.com
Nasdaq Futures Lead US Premarket Rally As Iran Ceasefire Reports Ease Fears Ahead Of Big Tech Earnings: Why NVDA, ORCL, SPCX, XOM, OTLK Are In Focus - stocktwits.com
OTLK Stock Surges On FDA Lytenava Application Resubmission After Successful Appeal - stocktwits.com
OTLK Stock Soars 28% After FDA Sets July Date For Lytenava Decision - stocktwits.com
Outlook Therapeutics Stock Price Forecast. Should You Buy OTLK? - StockInvest.us
People on the Move: Kevin Lundquist Named Chief Financial Officer of Outlook Therapeutics - BioBuzz
CFO at Outlook Therapeutics (NASDAQ: OTLK) gets 500,000 hiring options - Stock Titan
Outlook Therapeutics (NASDAQ: OTLK) CFO reports zero insider holdings - Stock Titan
Outlook Therapeutics Announces CFO Transition and Board Change - The Globe and Mail
Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™ - Sahm
Lundquist appointed chief financial officer at Outlook Therapeutics of Iselin - ROI-NJ
Outlook Therapeutics Names Kevin Lundquist CFO Ahead of Lytenava U.S. Launch - visionmonday.com
Outlook Therapeutics, Inc. Announces CFO Changes, Effective September 1, 2026 - marketscreener.com
OTLK Stock Rocket Nearly 140%: FDA's Lytenava FDR Approval Pushes Stock On Track For Best Week On Record - Stocktwits
Outlook Therapeutics(OTLK) Stock Options Chain | Quotes & News - Moomoo
Outlook Therapeutics (OTLK) investor held to 9.99% cap - Stock Titan
Outlook Therapeutics Inc (OTLK) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Outlook Therapeutics, Inc. 2026: Revenue $8.7K, EPS ($0.15) — 10-Q Summary - TradingView
Outlook Therapeutics (OTLK) wins FDA exclusivity but holds limited cash - Stock Titan
Brookline Capital cuts Outlook Therapeutics stock price target on model update - Investing.com
Outlook Therapeutics delays quarterly SEC filing - TipRanks
META_TITLE_QUOTE - Yahoo Finance
OTLK Q3 Earnings Call Maps LYTENAVA U.S. Launch and Sales Ramp - Yahoo Finance
Outlook Therapeutics Insider Bought Shares Worth $2,499,999, According to a Recent SEC Filing - moomoo.com
Outlook Therapeutics Posts Q3 Financials, Raises Funds for Lytenava Launch - visionmonday.com
symbol__ Stock Quote Price and Forecast - CNN
Outlook Therapeutics Inc (OTLK) Stock News Today - TradingKey
MSN Money - MSN
Outlook Therapeutics CEO Robert Jahr acquires shares and warrants for $0 - Investing.com South Africa
Outlook Therapeutics (OTLK) Stock May Be No Bargain With Approval But Weak Balance Sheet - Yahoo Finance
Outlook Therapeutics (OTLK) Stock Looks Fully Valued While Book Value Stays Unclear - simplywall.st
Outlook Therapeutics CFO Kenyon acquires 101,010 shares By Investing.com - Investing.com South Africa
Outlook Therapeutics (OTLK) CEO purchases 151,515 shares and matching warrants - Stock Titan
Outlook Therapeutics, Inc. 2026 Q3ResultsEarnings Call Presentation (NASDAQ:OTLK) 2026-08-14 - Seeking Alpha
Outlook Therapeutics director Ghiath Sukhtian buys $2.5m in shares By Investing.com - Investing.com Australia
Outlook Therapeutics director Ghiath Sukhtian buys $2.5m in shares - Investing.com
Outlook Therapeutics CFO Kenyon acquires 101,010 shares - Investing.com
Outlook Therapeutics (OTLK) investor GMS Ventures reports 16.4% beneficial stake - Stock Titan
Outlook Therapeutics (OTLK) insider-linked entity buys 2.5M shares plus 2.5M warrants - Stock Titan
Outlook Therapeutics (OTLK) CFO Lawrence Kenyon buys 101K shares plus 101K warrants - Stock Titan
OTLK Q3 FY2026 earnings call - finance.biggo.com
0.86%
0.31%
大文字化:
|
ボリューム (24 時間):